Nexvet Biopharma Public Limited Company Securities Litigation
On or around 08/02/2017 (Notice of voluntarily dismissal)
Filing Date: May 30, 2017
According to the Complaint, on April 13, 2017, Nexvet and Zoetis issued a joint press release announcing that they had entered into a Transaction Agreement (the "Merger Agreement") to sell Nexvet to Zoetis. Under the terms of the Merger Agreement, Zoetis will acquire all outstanding shares of Nexvet for $6.72 in cash per Nexvet common share (the "Merger Consideration"). The Proposed Transaction is valued at approximately $85 million.
On May 11,2017, Nexvet filed a Preliminary Proxy Statement on Schedule 14A (the "Proxy") with the SEC. The Complaint alleges the Proxy, which recommends that Nexvet stockholders vote in favor of the Proposed Transaction, omits and/or misrepresents material information concerning, among other things: (i) Nexvet's management's projections, utilized by the Company's financial advisor, Evercore Group L.L.C. ("Evercore") in its financial analyses; (ii) the valuation analyses prepared by Evercore in connection with the rendering of its fairness opinion; (iii) material omissions concerning Evercore's potential conflicts of interest; and (iv) material information concerning the sale process leading up to the Proposed Transaction.
On August 2, 2017, Plaintiff filed a Notice voluntarily dismissing this action.
Company & Securities Information
Defendant: Nexvet Biopharma Public Limited Company
Industry: Biotechnology & Drugs
Ticker Symbol: NVET
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Stephen Bushansky, et al. v. Nexvet Biopharma Public Limited Company, et al.
COURT: N.D. California
DOCKET #: 17-CV-03099
JUDGE: Hon. Jon S. Tigar
DATE FILED: 05/30/2017
CLASS PERIOD START: 04/13/2017
CLASS PERIOD END: 05/30/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
WeissLaw LLP (Beverly Hills)
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of the Federal Securities Laws
Notice of Voluntary Dismissal Pursuant to Fed. R. CIV. P.41(a)(1)(A)
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available